1.39k followers • 10 symbols Watchlist by Yahoo Finance
This basket consists of stocks that benefit from the needs of aging baby boomers.
It’s not enough, and investors know it. The Botox maker late Friday said it plans to split the CEO and chairman roles – a goal of hedge-fund holder Appaloosa Management – but only after an unspecified future “leadership transition.” It seems that current CEO and Chairman Brent Saunders likes being his own boss.
What’s Ahead for KMB and CL Stock?(Continued from Prior Part)Challenges continue to hurt sales and earningsKimberly-Clark (KMB) has beaten analysts’ sales estimates in the past two quarters, thanks to higher net prices. However, its sales have
What’s Ahead for KMB and CL Stock?Stock performance Kimberly-Clark (KMB) and Colgate-Palmolive (CL) have been strong this year, driven by improved organic sales due to higher pricing. However, near-term sales and earnings weakness could weigh on
Allergan stock was trading down as shareholders digested its 2019 proxy statement, in which the company butted heads with activist investor Appaloosa.
Coty (COTY) is largely benefitting from strength of its Luxury segment that accounted for about 40% of the top line in Q2. However, supply-chain hurdles continue to mar Consumer Beauty unit.
At the same time, others warn the Democrats will keep attacking the president, ratcheting up the rancor and threatening long-term deals on government spending and the deficit. Big banks, including JPMorgan Chase & Co., Bank of America Corp. and Citigroup Inc., which were hard hit last week, were little changed ahead of the open.
UnitedHealth Group Incorporated (NYSE:UNH) shareholders, and potential investors, need to understand how much cash the business makes from its core operational activities, as well as how much is invested backRead More...
Top US Companies Impacted by Slowing European EconomyUS stock marketEarly on March 22, US stock indexes were trading on a negative note. On March 21, the stock indexes ended on a bullish note. On March 21, the S&P 500 Index, the NASDAQ
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
What's Ahead for Church & Dwight and Clorox?(Continued from Prior Part)Valuation a concernThe majority of analysts covering Church & Dwight (CHD) and Clorox (CLX) stock maintain a neutral outlook despite better growth prospects among peers.
Positive development on the trade war front and the Fed???s dovish monetary stance are likely to be long-term catalysts for the blue-chip index.
Share are up 15% year to date, helped by the FDA’s acceptance of new applications for Botox. Still, questions remain about the health of the drugmaker’s pipeline and earnings profile.
WellCare Health (WCG) unit introduces a unique mobile app, Atlas Compass, to assist PBM members to manage their pharmacy health information.
What's Ahead for Church & Dwight and Clorox?(Continued from Prior Part)Top line to sustain momentum Clorox (CLX) could continue to report healthy sales growth despite pressure on net sales from currency volatility. Management expects its top
Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.
Riding high on solid segmental performances, Universal Health (UHS) promises to reap great benefits for investors. However, its debt load bothers.
What's Ahead for Church & Dwight and Clorox?(Continued from Prior Part)CHD’s top line could continue to grow Church & Dwight (CHD) has impressed investors with its stellar sales performance in the recent past. The company’s top line has
Service Corp. (SCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's Ahead for Church & Dwight and Clorox?Stock performance Church & Dwight (CHD) and Clorox (CLX) have underperformed peers so far this year as margin woes and high valuations are keeping investors on the sidelines. However, we expect
The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.